- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01605890
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients (VIH-2)
ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75018
- Hopital Bichat-Claude Bernard
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥18 years
- HIV-2 mono infection, confirmed by ELISA and Western Blot test or Immunoblot,
- antiretroviral treatment-naive, whatever the duration and indication of prior treatments,
- indication to treatment, with at least one of the following criteria : type B or C events, CD4 lymphocytes count below 500/mm3 at screening-visit or CD4 lymphocytes count decrease of at least 50 cell/µL/year over the last 3 years with the last CD4 lymphocytes count within -/+ 10 % of the nadir, plasma HIV-2 RNA load over or equal to 100 copies/mL at screening-visit,
- Pneumocystis prophylaxis if CD4 lymphocytes count below 200/mm3, combined to a toxoplasmosis prophylaxis in case of a positive toxoplasmosis serology,
- French residency for at least one year,
- Written informed consent, signed by the participant and the investigator (at the latest on the screening-visit and prior any study related intervention)
- Affiliate or beneficiary of a social security system (State Medical Assistance is not a social security scheme).
Exclusion Criteria:
- Absence of effective contraception method(women),
- Pregnancy, breastfeeding or wish for pregnancy during the trial,
- Curative treatment of a progressive opportunistic infection not compatible with those evaluated in the present study,
- Malignant or tumorous affection requiring chemotherapy or radiotherapy,
- Decompensated cirrhosis,
- Viral hepatitis C with a Metavir score over F2,
- Hemoglobinemia below 7g/dL, polynuclear neutrophils below 500/mm3, platelets below 50 000/mm3, creatinine clearance below 50 mL/mn, transaminase, alkaline phosphatase or bilirubin over 2.5N,
- Contraindication to one of the excipients of study treatments,
- Insuline-dependent diabetes mellitus not well controlled (with glycated haemoglobin (HbA1C) over 7%),
- Long-term corticosteroid treatment (more than 3 weeks of treatment),
- Judicial protection, legal guardianship,
- Participation in other therapeutic trial or comprising an exclusion period ongoing at the time of the screening-visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: raltegravir / emtricitabine / tenofovir disoproxil fumarate
|
emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD. raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants in Therapeutic Success
Time Frame: at Week 48
|
The participants will be considered in therapeutic success at Week 48 if they did not present any of the following events:
|
at Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Change in CD4 Lymphocytes Count at Week 12
Time Frame: between Week 0 and Week 12
|
between Week 0 and Week 12
|
|
Number of Clinical and Biological Events
Time Frame: from Week 0 to Week 48
|
from Week 0 to Week 48
|
|
Median Change of CD4 Lymphocytes at Week 48
Time Frame: between Week 0 and Week 48
|
between Week 0 and Week 48
|
|
Percentage of Patients With Plasma HIV-2 RNA < 40 Copies/mL
Time Frame: between Week 0 and Week 48
|
between Week 0 and Week 48
|
|
Number of Participants With Clinical Progression
Time Frame: from Week 0 to Week 48
|
Clinical progression is defined as the switch:
|
from Week 0 to Week 48
|
Minimal Observed Percentage of Participants With Moderate to Good Adherence Evaluated With ANRS Self-administered Questionnaire of Adherence
Time Frame: from Week 4 to Week 48
|
from Week 4 to Week 48
|
|
Number of Virological Failure Participants With Resistance Mutations
Time Frame: from Week 0 to Week 48
|
Virological failure is defined as plasma HIV-2 RNA load over or equal to 100 copies/mL after plasma HIV-2 RNA load below 100copies/mL, confirmed with a retest within the 4 following weeks.
The number and type of mutations in the RT and integrase genes compared to week 0 is being reported.
|
from Week 0 to Week 48
|
Number of Participants With Treatment Switch or Discontinuation
Time Frame: from Week 0 to Week 48
|
Overall (regardless of the molecule)
|
from Week 0 to Week 48
|
Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 48
Time Frame: at Week 48
|
at Week 48
|
|
Minimal Median of the Lower Dimension Out of the 4 Dimensions of the Quality of Life Questionnaire
Time Frame: from Week 0 to Week 48
|
The quality of life questionnaire is the Professional Quality of Life (PROQOL) questionnaire, including 4 dimensions: Physical health and symptoms, Relationship with others, Mental and cognitive functioning and Treatment impact For each scale, a score ranging from 0 (the worst answer) to 100 (the best answer) is calculated. |
from Week 0 to Week 48
|
Number of Participants With >6 Copies of HIV-2 DNA in Plasma at Week 24
Time Frame: Week 24
|
Week 24
|
Collaborators and Investigators
Investigators
- Study Chair: Sophie Matheron, Pr, Hopital Bichat-Claude Bernard
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Tenofovir
- Emtricitabine
- Raltegravir Potassium
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Other Study ID Numbers
- 2011-005038-20
- ANRS 159 VIH-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-2 Infection
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaboratorsTerminated
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
ANRS, Emerging Infectious DiseasesUnknown
-
ANRS, Emerging Infectious DiseasesCompleted
-
University of WashingtonGilead Sciences; Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF,...Completed
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Kenya Medical...CompletedHIV Infections | HSV-2 InfectionKenya
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
Clinical Trials on emtricitabine / tenofovir disoproxil fumarate / raltegravir .
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompleted
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkCompletedHIV InfectionsSouth Africa, Uganda, Zimbabwe
-
National Institute of Allergy and Infectious Diseases...Adult AIDS Clinical Trials GroupCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHIV InfectionsUnited States, Puerto Rico
-
David A Wohl, MDMerck Sharp & Dohme LLCCompletedHIV InfectionsUnited States
-
University of North Carolina, Chapel HillCompleted
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV Infections | HIV-1 InfectionsKenya, Uganda
-
AbbottMerck Sharp & Dohme LLCCompletedHuman Immunodeficiency Virus InfectionUnited States, Canada, France, Italy, Poland, Puerto Rico, Spain
-
Fenway Community HealthMerck Sharp & Dohme LLCCompleted
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Completed